Erratum to: Intensive Care Med (2008) 34:1935–1947 DOI 10.1007/s00134-008-1266-6
Due to an oversight by the authors, incorrect data appeared in Table 2. The table is reproduced here with the corrected item in bold type.
Table 2.
Serious bleeding rates in clinical trials of drotrecogin alfa (activated)
| Study | Placebo n (%) | DAA n (%) | P |
|---|---|---|---|
| PROWESS | 17 (2.0) | 30 (3.5) | 0.06 |
| PROWESS (CNS) | 1 (0.1) | 2 (0.2) | NS |
| ADDRESS | 28 (2.2) | 51 (3.9) | 0.01 |
| ADDRESS (Day 0–6) | 15 (1.2) | 31 (2.4) | 0.02 |
| ADDRESS (CNS) | 5 (0.4) | 6 (0.5) | 0.72 |
| RESOLVE | 16 (6.8) | 16 (6.7) | 0.97 |
| RESOLVE (Day 0–6) | 8 (3.4) | 9 (3.8) | 0.83 |
| RESOLVE (CNS) | 5 (2.1) | 11 (4.6) | 0.13 |
| ENHANCE | – | 155 (6.5) | – |
Day 0–6: any serious bleeding event occurring during the DAA infusion period
CNS central nervous system bleeding
Footnotes
The online version of the original article can be found under doi:10.1007/s00134-008-1266-6.